For years, the primary way to track the health of a person living with HIV was the CD4 count. It provided a snapshot of the immune system's strength. While still useful, the focus of Antiretroviral Therapy (ART) monitoring in India has decisively shifted. The new gold standard is the viral load test, which directly measures how well ART is working to stop the virus from replicating.

This change is guided by the National AIDS Control Organisation (NACO), which sets the clinical protocols for HIV management across the country. A viral load test counts the number of HIV RNA copies in a milliliter of blood. It’s the most accurate indicator of treatment success, telling doctors not just how the patient is feeling, but how effectively their medication is controlling the virus.

Achieving an undetectable viral load is a crucial milestone. It signifies that the amount of HIV in the blood is so low it cannot be measured by standard tests. This leads to the powerful public health message: Undetectable = Untransmittable, or U=U. When a person maintains an undetectable viral load through consistent ART, they cannot transmit HIV to their sexual partners. This understanding has revolutionized life for people with HIV, reducing stigma and improving quality of life.

India's national program has largely transitioned to regimens based on Dolutegravir (DTG), a type of Integrase Inhibitor (INSTI). DTG-based treatments are highly effective, have a high barrier to resistance, and are generally well-tolerated. They work by blocking an enzyme the virus needs to insert its genetic material into the DNA of human cells, effectively halting replication.

While highly effective against HIV, these newer medications require careful monitoring for potential metabolic side effects. It’s now standard practice to regularly check for:

Managing these comorbidities is a key part of long-term HIV care. Physicians at ART centers monitor these parameters through baseline and periodic blood tests. This proactive approach ensures that the benefits of powerful antiretroviral drugs are not offset by other health risks.

Sometimes, a person's viral load may not become suppressed or may increase after a period of being undetectable. This is known as virologic failure. The first step is to assess the patient's adherence to their medication schedule, as inconsistent dosing is the most common reason for failure.

If adherence is good but the viral load remains high, the next step is to consider HIV drug resistance. The virus can mutate, developing changes that make it less susceptible to specific antiretroviral drugs. To investigate this, an HIV drug resistance test is performed. This genetic test analyzes the virus's RNA to identify specific mutations associated with resistance to different classes of ART drugs.

The results of the resistance test are crucial. They guide the physician in selecting a new, effective combination of drugs for a second-line or third-line regimen, giving the patient the best possible chance to achieve viral suppression again.

Modern ART management in India is a dynamic process. It balances powerful medications with careful monitoring of their effectiveness and side effects, ensuring people with HIV can lead long, healthy lives.

Let's check your understanding of these monitoring concepts.